0
Prevtec Microbia Inc. is pleased to announce that its German subsidiary, Prevtec Microbia GmbH, received the market authorization from the European Commission for Coliprotec® F4/F18 in the European Union. Coliprotec® F4/F18 is the first single dose oral vaccine intended for active immunization of pigs against enterotoxigenic F4- and F18-positive Escherichia coli, the two most important agents of post-weaning diarrhea (PWD), a major cause of economic loss for swine producers.
Through preventative immunization, Coliprotec® F4/F18 contributes to the health of piglets by reducing the incidence of moderate to severe PWD and the fecal shedding of enterotoxigenic F4- and F18-positive Escherichia coli from infected pigs.
“We are very pleased to receive the European Commission’s approval for this bivalent vaccine at a time when swine producers and veterinarians are looking for alternatives to antibiotics and are conscious of sustainable farming” says Michel Fortin, President and CEO of Prevtec Microbia Inc.
“The approval of Coliprotec® F4/F18 is the result of strong teamwork between Prevtec Microbia and Klifovet AG, and following the introduction of our first vaccine Coliprotec® F4 more than a year ago, in the European Union, this new bivalent vaccine brings even more depth of prevention for swine producers and veterinarians” added Dr. Éric Nadeau, Vice-President Scientific Affairs. “We are delighted to bring Coliprotec® F4/F18 across Europe with our partner Elanco.”
"As a major breakthrough in the fight against post-weaning diarrhea in pigs, Coliprotec® F4/F18 is a significant addition to our range of vaccines in Europe. We see this as a further opportunity to deliver innovation and value to our customers, offering them a new vaccine to protect piglets against PWD” said Ramiro Cabral, Head of Elanco Operations for Europe, Middle East and Africa.
Coliprotec® F4/F18 has been developed by Prevtec Microbia and will be distributed by Elanco Animal Health in the European Union.
January 13, 2017 - Elanco
